Immunotherapy and combined treatment in gastric cancer

Ruqian Ji

DOI: https://doi.org/10.54254/2753-8818/27/20240718

2023-12-20

Abstract:Gastric Carcinoma (GC) ranks as the fifth inducing cause for cancer incidence, and its the fourth inducing reason for cancer-related mortality. Traditional treatments, which involve a combination of chemotherapy and surgical resection, often yield unfavorable prognoses for gastric cancer patients, especially for those with advanced stages or metastases. Immunotherapy has recently emerged as the significant focus in the treatment of advanced gastric cancer, particularly for patients with MSI-H/dMMR. Medications targeting PD-1, such as nivolumab and Keytruda, have gained marketing approval in recent years. Additionally, some biomarkers like HER2, FGFR, and VEGF have shown positive efficacy in clinical research. However, resistance to immunotherapy remains a significant challenge, and the effectiveness of these pharmaceuticals often lasts only about a year for patients suffering advanced gastric cancer. Consequently, theres a need to explore new immune checkpoint inhibitors and discover novel combination therapy approaches. This review is aimed at introducing several latest immune checkpoint inhibitors currently in clinical phases or in pre-clinical stages, alongside innovative combination strategies for treating gastric cancer.